Thrombus - 2008

The pathogenesis of Lemierre’s syndrome
Samreen Siddiq, Owen Williams and Andrew Mumford
pp 1-3
Thrombosis of the internal jugular vein (IJV) is an uncommon condition that is usually associated with direct trauma from indwelling venous catheters, or through intravenous drug abuse. Less commonly, IJV thrombosis may be precipitated by localised sepsis in oropharyngeal tissues adjacent to the IJV.
Comment: Oral anticoagulation for atrial fibrillation
Peter Rose
pp 2-2
The benefit in symptomatic atrial fibrillation (AF) of oral anticoagulant therapy is well established in clinical trials. Overall, stroke is five to six times more prevalent in patients with AF, with a 1% risk per year for patients over 65 years with no risk factors, rising to 12% per year for patients over 65 years with previous stroke, transient ischaemic attack (TIA) or venous thromboembolic disease.
Multidisciplinary management of VTE
Peter Rose and Grace O’Hare
pp 4-5
The modern day management of venous thromboembolism (VTE) is best undertaken using a multidisciplinary approach. This involves a formal assessment with core members providing the clinical, diagnostic and treatment input to the management plan. It is important that the diagnosis is confirmed, as radiological investigations can often be misinterpreted. Each patient requires a risk assessment for recurrence of VTE and bleeding risk.
Disseminated intravascular coagulation
Louise Knowlson and Katie Randall
pp 6-8
Disseminated intravascular coagulation (DIC) is a complicated, life-threatening condition that is usually coupled with an equally serious underlying cause. In this article, the diagnosis of patients with DIC and practical issues in the management of this diverse group are discussed.
Why use computerised decision support software?
David Fitzmaurice
pp 10-10
Oral anticoagulation management is a complicated business because of the nature of oral anticoagulants. Not only do they have a very narrow therapeutic window, they are also affected by numerous drugs, foods, alternative medications and, of course, alcohol.

Thrombus was previously supported by Bayer from 2014 to 2016, by Boehringer Ingelheim from 2009 to 2013, by sanofi-aventis from 2007 to 2008 and by Leo Pharma from 1998 to 2006.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsor, publisher, Editor or Editorial Board. Accordingly the sponsor, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title Thrombus is the property of Hayward Medical Publishing and PMGroup Worldwide Ltd and, together with the content, is bound by copyright. Copyright © 2019 PMGroup Worldwide Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to:

ISSN 1369-8117 (Print)  ISSN 2045-7855 (Online)